Brief: Tenaya Therapeutics Q2 Net Income USD -29.431 Million Vs. IBES Estimate USD -31.5 Million
08/08/2024 21:05
Aug 08 (Reuters) - Tenaya Therapeutics Q2 operating expenses USD 30.823 million. * Q2 operating income USD -30.823 million vs. IBES estimate USD -32 million * Q2 basic EPS USD -0.34 * Q2 pretax profit USD -29.431 million vs. IBES estimate USD -31.5 million
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027